Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
|Articles|March 2, 2018
Catalent Expands Clinical Supply Capabilities
Author(s)BioPharm International Editors
Catalent completes $4.6 million expansion at Singapore clinical supply facility and marks 20 years in the region.
Advertisement
Catalent Pharma Solutions announced on Feb. 28, 2018 the completion of a two-year, $4.6 million expansion at its Singapore clinical supply facility. The expansion added GMP space for secondary packaging, doubled ambient storage, and quadrupled cold storage capacity at the site. The site, which has almost tripled in size since opening in 1998, measures almost 20,000-sq. ft. and is described by the company as a key strategic hub in its Asia-Pacific network and global clinical supply business.
“We are particularly pleased to have completed the expansion in a year that marks the 20th anniversary of what was Catalent’s first facility in the Asia-Pacific region,” said Bernie Clark, VP Marketing, Catalent Clinical Supply Services in a company press release. “Supported by many long-serving employees, the Singapore site has undergone tremendous growth over the past two decades and now routinely distributes to 18 countries in the region.”
The company has facilities in the United States, United Kingdom, Germany, Japan, and China, and more than 50 audited depots.
Source:
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5